Tendon soreness often changes when the movement changes

A steady amount of movement gives a sore tendon time to settle

First, reduce the movement if it sharply raises your soreness. You might grip more lightly, reach overhead less, or take shorter walks. Complete rest can leave the tendon unready for normal use. Keep doing an amount that doesn't cause a sharp or lasting ache.

Add more only after the current amount feels manageable. A sudden busy day can undo several calmer days. Supportive shoes may help when heel soreness follows standing or walking. The right exercise depends on which tendon hurts and what the exam finds.

Sudden weakness needs a different response. Seek prompt care if you can't raise your arm after an injury. A shoulder that changes shape or quickly swells also needs an exam. These signs may mean a sudden injury rather than soreness from repeated use.

Increase weight, distance, or activity time in small amounts.

PRP is a blood-based shot considered for lasting tendon soreness

Long-lasting soreness needs an exam before another treatment is chosen. Shoulder pain may begin in a tendon, joint, neck, or nearby tissue. Outer elbow soreness can also involve a joint or nerve. The exam keeps the care aimed at the sore tissue.

QC Kinetix may offer biologic therapies, meaning shots prepared from your blood. PRP means platelet-rich plasma, the pale liquid kept when clinic equipment spins your drawn blood. Spinning leaves that liquid with more platelets. Platelets are small blood pieces that start clotting and early repair after injury. The clinician gives the prepared liquid to the sore tendon.

For lasting outer-elbow soreness, cortisone helped more before two months. PRP helped more from six months onward in the review. The research didn't show one result for every tendon. It also didn't promise how much relief one person would feel.

Ask when you may return to your normal work after the shot. The choice must fit both the sore tendon and your usual activity.

Sources

1. A meta-analysis of 11 RCTs (730 patients) with lateral epicondylitis found the timing reverses the answer: corticosteroid was significantly BETTER than PRP in the short term (under 2 months: VAS mean difference 0.93 favouring steroid; DASH 10.23 favouring steroid), the two did not differ at 2-6 months, and PRP was significantly better at 6 months or more (VAS -2.18; DASH -8.13; Mayo Elbow +16.53).

   Xu Y, et al. — Platelet-Rich Plasma Has Better Results for Long-term Functional Improvement and Pain Relief for Lateral Epicondylitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465231213087.

2. A meta-analysis of 27 RCTs (1,779 patients) across rotator cuff injury, lateral epicondylitis, plantar fasciitis and tenosynovitis found no PRP advantage at one month anywhere, and in some tendons corticosteroid was better early; PRP overtook corticosteroid at 3 months for rotator cuff VAS and at 6 months for plantar fasciitis VAS and AOFAS and for tenosynovitis VAS.

   Ye Z, et al. — Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis.. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-08566-3.

3. A meta-analysis of 24 RCTs (1,653 participants) with plantar fasciitis found PRP produced significantly better VAS pain than corticosteroid at 3 and 6 months but not at 1 month or 12 months, and better AOFAS function scores at 3, 6 and 12 months. Plantar fascia thickness did not differ significantly at any time point.

   Zuo A, et al. — Platelet-Rich Plasma Versus Corticosteroids in the Treatment of Plantar Fasciitis: A Systematic Review and Meta-analysis.. American Journal of Physical Medicine & Rehabilitation, 2025. DOI: 10.1097/PHM.0000000000002677.

4. A meta-analysis with meta-regression of 10 Level I-II studies (696 patients) of PRP augmentation during rotator cuff repair classified trials by whether the platelet concentration factor exceeded a 4-fold increase over whole blood. Neither patient-reported outcomes nor retear rates differed between high-dose and low-dose PRP - a direct test of the 'more platelets is better' premise, which it did not support in this setting.

   Lim JJ, et al. — Platelet Concentration Does Not Influence Clinical Efficacy and Retear Rates of Rotator Cuff Repair With Platelet-Rich Plasma: A Systematic Review and Meta-analysis With Meta-Regression.. American Journal of Sports Medicine, 2026. DOI: 10.1177/03635465261434001.

5. The AAOS patient-education FAQ on orthobiologics states that because orthobiologics are relatively new the evidence supporting their use is LIMITED, that rigorous testing of effectiveness in most orthopedic conditions is lacking, and that preliminary results are encouraging but hard to evaluate. It names tendinopathies such as tennis elbow, pain from early knee osteoarthritis, adjunct healing after rotator cuff repair, and avascular necrosis as the settings where biologic therapies have shown promise, and notes that stem cell treatments not derived from the patient's own body and further manipulated in a laboratory can only be offered inside an FDA-approved clinical trial.

   American Academy of Orthopaedic Surgeons — Orthobiologics (Regenerative Medicine) FAQ. OrthoInfo (AAOS), 2024.

6. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.